Photoacoustic imaging to tell how aggressive prostate cancer is
Detecting prostate cancer aggressiveness using photoacoustic chemical imaging with photoacoustic spectral analysis
This project uses a new ultrasound‑like photoacoustic scan combined with tiny targeted nanoparticles to find prostate tumors and tell if they are likely to be aggressive in men being evaluated for prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11270841 on NIH RePORTER |
What this research studies
You would receive a real‑time photoacoustic scan that detects both the microscopic gland structure and abnormal chemical conditions in prostate tissue. Tiny biocompatible hydrogel nanoparticles designed to bind cancer cells and carry contrast agents make abnormal areas light up on the scan. The team will combine this imaging signal with spectral analysis to distinguish aggressive tumors from less dangerous ones. Work will move from lab and animal testing toward testing the technique in clinical settings to improve detection and characterization of prostate cancer.
Who could benefit from this research
Good fit: Men undergoing evaluation for prostate cancer—for example those with elevated PSA, suspicious MRI findings, or scheduled for prostate biopsy—are the most likely candidates.
Not a fit: Men without prostate cancer, those whose prostates cannot be accessed by the imaging approach, or people with specific contraindications to the nanoparticle agents may not benefit.
Why it matters
Potential benefit: If successful, this approach could find clinically important prostate cancers more reliably and guide better treatment decisions while reducing missed or under‑graded tumors.
How similar studies have performed: Photoacoustic imaging and nanoparticle contrast have shown promising results in preclinical studies, but clinical use for prostate cancer aggressiveness is still new.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Jo, Janggun — University of Michigan at Ann Arbor
- Study coordinator: Jo, Janggun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.